From 830bdf0709b0e480fb442e29fd938248bee31468 Mon Sep 17 00:00:00 2001 From: Miguel Brown Date: Mon, 11 Mar 2024 19:29:19 +0000 Subject: [PATCH] :pencil: shorten desc to meet length requirements --- STUDY_CONFIGS/tll_sd_aq9kvn5p_2019_case_meta_config.json | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/STUDY_CONFIGS/tll_sd_aq9kvn5p_2019_case_meta_config.json b/STUDY_CONFIGS/tll_sd_aq9kvn5p_2019_case_meta_config.json index ec418c4..6a40e73 100644 --- a/STUDY_CONFIGS/tll_sd_aq9kvn5p_2019_case_meta_config.json +++ b/STUDY_CONFIGS/tll_sd_aq9kvn5p_2019_case_meta_config.json @@ -166,7 +166,7 @@ }, "study": { "_comment": "see https://docs.cbioportal.org/5.1-data-loading/data-loading/file-formats#cancer-study for detailed specifics", - "description": "This study focuses on improving the treatment of relapsed T-cell acute lymphoblastic leukemia (T-ALL), a type of blood cancer with a poor prognosis. Currently, it is challenging to identify patients at high risk of relapse at the time of diagnosis. The study analyzes the genetic makeup of T-ALL patients from a clinical trial (AALL0434) to find genetic alterations that could help predict poor outcomes and guide alternative treatments. The research uses comprehensive genomic profiling techniques like RNA sequencing, DNA CNV analysis, WXS, and WGS. The specific goals are to identify recurrent genetic alterations associated with poor prognosis, discover novel genetic changes, and find germline genetic variants that make patients more susceptible to T-ALL and increased chemotherapy toxicity. The findings aim to advance our understanding of T-ALL and provide insights for better risk stratification and personalized therapies. KF, GMKF. For updates, please see here: Release Notes", + "description": "This study focuses on improving the treatment of relapsed T-cell acute lymphoblastic leukemia (T-ALL), a type of blood cancer with a poor prognosis. Currently, it is challenging to identify patients at high risk of relapse at the time of diagnosis. The study analyzes the genetic makeup of T-ALL patients from a clinical trial (AALL0434) to find genetic alterations that could help predict poor outcomes and guide alternative treatments. The research uses comprehensive genomic profiling techniques like RNA-seq, DNA CNV analysis, WXS, and WGS. The specific goals are to identify recurrent genetic alterations associated with poor prognosis, discover novel genetic changes, and find germline genetic variants that make patients more susceptible to T-ALL and increased chemotherapy toxicity. The findings aim to advance our understanding of T-ALL and provide insights for better risk stratification and personalized therapies. KF, GMKF. For updates, please see here: Release Notes", "groups": "PUBLIC", "cancer_study_identifier": "tll_sd_aq9kvn5p_2019", "type_of_cancer": "tll",